Insulet (PODD) has a tubeless-pump platform and consumables engine bigger than a one-device story.
Article excerpt
Insulet (PODD) has a tubeless-pump platform and consumables engine bigger than a one-device story. Insulet Corporation (PODD) is easy to misread as a single-product medtech company. The better lens is a platform business built around a growing installed base, recurring disposable-Pod sales, and a reimbursement model that lowers upfront friction for patients and payors. Insulet said in its 2025 annual report that each Pod is intended to be used for up to three days, and that its pay-as-you-go model helps the company generate an increasing portion of revenue from recurring disposable Pod sales as the user base expands. That model already shows up clearly in the numbers. Insulet reported more than 600,000 estimated active Omnipod users globally as of December 31, 2025, while full-year 2025 revenue rose 30.7% to $2.708 billion and total Omnipod revenue climbed 31.6% to $2.674 billion. In the first quarter of 2026, total revenue increased another 33.9% year over year to $761.7 million, with Omnipod revenue at $758.4 million. Thesis and why the one-device framing misses the platform story. The core investment case is not just that Omnipod is a popular insulin pump. It is that new patient starts create a repeat-purchase stream because the disposable Pod has to be replaced every few days. That makes the installed base more important than the hardware label. Insulet explicitly...
Keep reading with a free account
The rest of this article, and every signal for Insulet, is in your free account.
Extracted from this sentence
Insulet said in its fourth-quarter release that it launched Omnipod 5 in nine new markets during 2025, and in the first-quarter release it said Omnipod 5 and Omnipod Discover were launched in five countries in the Middle East, bringing Omnipod 5 availability to 19 countries.
